Neurological disorders are becoming one of the world’s biggest healthcare challenges.
More than 3.4 billion people were living with a neurological condition in 2021, according to the Global Burden of Disease study published in The Lancet Neurology. That means over 43% of the global population is affected by disorders involving the brain, spinal cord, or nervous system.
As populations age and diseases such as Alzheimer’s, Parkinson’s, and multiple sclerosis continue to rise, the demand for faster and more accurate diagnostic testing is accelerating. This is where Fujirebio has quietly built a strong position.
Source: https://www.towardshealthcare.com/insights/neurodiagnostics-market-sizing
Rather than competing across every diagnostic category, the company has focused on becoming a leader in neurological biomarkers, an area that is reshaping how brain diseases are detected and monitored.
A Global Brain Health Crisis Is Creating Demand for Better Diagnostics
| Neurological Disease Statistics | Latest Data |
|---|---|
| People living with neurological disorders | 3.4 billion |
| Annual neurological disorder deaths | More than 11 million |
| Disability-adjusted life years (DALYs) lost | 443 million |
| People living with dementia globally | More than 55 million |
| New dementia cases every year | Nearly 10 million |
| Alzheimer’s disease share of dementia | 60–70% |
The numbers explain why diagnostic innovation has become a healthcare priority.
The World Health Organization (WHO) estimates that dementia affects over 55 million people worldwide, with almost 10 million new cases diagnosed each year. Around 60% to 70% of these patients have Alzheimer’s disease.
Governments are also increasing investments in early diagnosis because treatment is most effective before irreversible brain damage occurs.
From Laboratory Specialist to Neurology Diagnostics Leader
Fujirebio has spent decades building expertise in in-vitro diagnostics (IVD).
Instead of focusing only on routine laboratory testing, the company invested heavily in biomarker research for neurodegenerative diseases.
Today, its diagnostic portfolio includes assays measuring biomarkers such as:
- Amyloid beta (Aβ40 and Aβ42)
- Total Tau
- Phosphorylated Tau (pTau181 and pTau217)
- Neurofilament Light Chain (NfL)
- Glial Fibrillary Acidic Protein (GFAP)
These biomarkers help clinicians identify biological changes associated with Alzheimer’s disease and other neurological disorders long before symptoms become severe.
Want to see the market opportunities, competitor strategies, and regional trends shaping your industry? Download a FREE customized sample report: https://www.towardshealthcare.com/download-sample/6745
Why Blood-Based Biomarkers Are Changing the Market
For years, diagnosing Alzheimer’s disease often required costly PET imaging or invasive cerebrospinal fluid testing.
Blood-based biomarker testing is changing that equation.
Simple blood samples can now provide important information about neurodegeneration, making testing more accessible for hospitals, neurologists, and community healthcare systems.
This shift is expected to improve patient access while reducing diagnostic costs and waiting times.
For healthcare providers, blood-based diagnostics also support earlier treatment decisions and patient monitoring.
Regulatory Progress Is Strengthening Fujirebio’s Position
Regulatory approvals have become one of Fujirebio’s biggest competitive advantages.
The company has introduced several advanced Alzheimer’s biomarker assays across global markets and continues collaborating with pharmaceutical companies developing disease-modifying therapies.
As new Alzheimer’s drugs require biomarker confirmation before treatment, reliable laboratory diagnostics become increasingly important.
This creates long-term demand not only from hospitals but also from clinical research organizations and pharmaceutical companies.
Governments Are Investing in Earlier Detection
Healthcare systems are shifting from treating advanced disease to identifying patients earlier.
The WHO’s Global Action Plan on the Public Health Response to Dementia encourages countries to strengthen early diagnosis, improve access to diagnostic services, and expand dementia care.
Meanwhile, the U.S. National Institute on Aging continues funding biomarker research through the Alzheimer’s Disease Research Centers, accelerating validation of blood-based diagnostic technologies.
Europe and Japan are also expanding precision medicine initiatives aimed at improving neurological disease diagnosis.
These public investments create favorable conditions for companies specializing in validated neurological biomarkers.
A Strategic Advantage Beyond Traditional Diagnostics
Many diagnostic companies provide broad laboratory testing.
Fujirebio has differentiated itself by becoming deeply specialized in neurological biomarkers.
Its strategy combines:
- Advanced biomarker discovery
- High-quality immunoassay development
- Global laboratory partnerships
- Pharmaceutical collaborations
- Regulatory expertise in neurodegenerative diseases
This specialization allows the company to compete in a high-value segment where scientific validation matters more than test volume.
Neurological disorders have become the leading cause of illness and disability worldwide, making early diagnosis one of healthcare’s fastest-growing priorities.
With 3.4 billion people affected globally and dementia cases expected to rise sharply as populations age, demand for reliable neurological diagnostics will continue expanding.
Fujirebio is well positioned in this evolving landscape through its strong expertise in Alzheimer’s biomarkers, blood-based diagnostic innovation, and partnerships across the pharmaceutical and clinical laboratory ecosystem. As precision medicine becomes a standard part of neurological care, companies with proven biomarker capabilities are likely to play an increasingly important role in helping clinicians detect disease earlier and improve patient outcomes.
Get Easy Access
Access our exclusive, data-rich dashboard dedicated to the diagnostics market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium